aclarubicin and Pericardial-Effusion

To determine the efficacy of aclarubicin hydrochloride in local control of malignant pericardial effusion, the authors carried out a trial of pericardial drainage with local administration of this agent in five patients, whose effusions had produced cardiac tamponade. All patients were women, and their primary cancers, all initially treated surgically, had arisen in the breast (two patients), or lung (three patients). Mean patient age was 54.2 years (range, 43-62). In four patients, improvement permitted removal of the drainage catheter. Two patients (40%) had a complete remission of the malignant pericardial effusion. The other three patients were difficult to evaluate because nonpericardial metastases limited their survival. All patients, however, showed disappearance of malignant cells from the pericardial sac with no cytopathologically demonstrable recurrence. In our few patients, intrapericardial aclarubicin appeared to be highly effective against malignant pericardial effusion.

Topics: Aclarubicin; Adult; Antineoplastic Agents; Breast Neoplasms; Cardiac Tamponade; Catheterization; Drainage; Female; Humans; Injections, Intralesional; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Pericardial Effusion; Treatment Outcome